Group 1 - Jimin Health has experienced a significant increase, with 6 consecutive trading limits reached in 12 days [1] - Shutai Shen has risen over 7%, indicating strong market interest [1] - Hot景生物 has seen an increase of over 5%, reflecting positive investor sentiment [1] Group 2 - Other companies such as Meidi Xi, Guangsheng Tang, and Borui Pharmaceutical have also shown upward trends in their stock prices [1]

9月11日，博瑞医药大宗交易成交2.4万股，成交额200.4万元，占当日总成交额的0.19%，成交价83.5 元，较市场收盘价92.71元折价9.93%。 | 交易日期 证券商标 | | 证券代码 | 成交价(元) 成交盒额(万元) 成交量(*) 买入营业部 | 要出营业部 | 是否为变场 | | --- | --- | --- | --- | --- | --- | | | | | 机构专用 | 国投证券股份有限 | | | 2025-09-11 | 博瑞医药 | 688166 | 83.5 200.4 2.4 | AN MANAGE AND | Kiz | ...

自 2025 年 8 月 22 日至 2025 年 9 月 11 日，博瑞生物医药（苏州）股份 有限公司（以下简称"公司"）股票满足连续 30 个交易日中有 15 个交易日收盘 价格不低于当期转股价格的 130%（即 45.16 元/股），已触发《博瑞生物医药（苏 州）股份有限公司向不特定对象发行可转换公司债券募集说明书》（以下简称"可 转债募集说明书"）中规定的有条件赎回条款。 公司于 2025 年 9 月 11 日召开第四届董事会第十一次会议，审议通过《关 于不提前赎回"博瑞转债"的议案》，决定本次不行使"博瑞转债"的提前赎回 权利，不提前赎回"博瑞转债"。 未来三个月内（即 2025 年 9 月 12 日至 2025 年 12 月 11 日期间），如"博 瑞转债"再次触发有条件赎回条款，亦不行使提前赎回权利。公司以 2025 年 12 月 12 日（若为非交易日则顺延）为首个交易日重新计算，若再次触发"博瑞转 债"的有条件赎回条款，届时公司董事会将再次召开会议决定是否行使"博瑞转 债"提前赎回的权利。 证券代码：688166 证券简称：博瑞医药 公告编号：2025-063 转债代码：118004 转债简 ...

民生证券股份有限公司 关于博瑞生物医药（苏州）股份有限公司 不提前赎回"博瑞转债"的核查意见 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为博瑞生 物医药（苏州）股份有限公司（以下简称"博瑞医药"、"公司"或"发行人"）向 不特定对象发行可转换公司债券的保荐机构，根据《证券发行上市保荐业务管 理办法》《上海证券交易所上市公司自律监管指引第1号——规范运作》《上海 证券交易所上市公司自律监管指引第11号——持续督导》及《上海证券交易所 上市公司自律监管指引第12号——可转换公司债券》等有关规定，对博瑞医药 本次不提前赎回"博瑞转债"的事项进行了审慎核查，核查情况及核查意见如下： 一、可转债的发行上市情况 经中国证券监督管理委员会《关于同意博瑞生物医药（苏州）股份有限公司 向不特定对象发行可转换公司债券注册的批复》（证监许可[2021]3551号）同意 注册，公司向不特定对象共计发行465万张可转换公司债券，每张面值为人民币 100元，按面值发行。本次发行合计募集资金人民币465,000,000元，扣除不含税 的发行费用人民币8,168,820.75元后，募集资金净额为人民币456,831,179 ...

Core Viewpoint - 博瑞生物医药（苏州）股份有限公司 has triggered conditional redemption terms for its convertible bonds due to stock price performance, but has decided not to exercise the early redemption option to protect investor interests [1] Group 1: Redemption Conditions - The company’s stock has met the condition of closing prices being at least 130% of the conversion price (45.16 CNY/share) for 15 out of 30 consecutive trading days from August 22 to September 11, 2025 [1] - The board of directors approved the decision not to redeem the "博瑞转债" early on September 11 [1] Group 2: Future Considerations - The company will not exercise the early redemption right for the next three months (from September 12 to December 11) even if the redemption conditions are met again [1] - No trading of "博瑞转债" has occurred by relevant parties within the six months prior to the satisfaction of the redemption conditions [1]

Group 1 - The core viewpoint is that the 科创100ETF fund has shown significant growth, with a 3.63% increase and a total scale of 57.64 billion, making it the largest in its category [1][2] - Semiconductor stocks are experiencing a strong performance, driven by Oracle's announcement of a 359% year-on-year increase in unmet performance obligations, reaching 455 billion [1] - The ongoing global AI computing power competition is expected to drive demand in the semiconductor and consumer electronics sectors, with a focus on innovation and recovery in demand [1] Group 2 - The 科创100ETF fund closely tracks the 上证科创板100 index, which selects 100 securities from the Sci-Tech Innovation Board based on market capitalization and liquidity [2] - As of August 29, 2025, the top ten weighted stocks in the 上证科创板100 index account for 23.82% of the index, including companies like 东芯股份 and 华虹公司 [2]

Group 1 - The core point of the news is that 博瑞医药 (Borui Pharmaceutical) experienced a decline of 5.04% in its stock price, reaching 92.13 yuan per share, with a trading volume of 784 million yuan and a turnover rate of 1.97%, resulting in a total market capitalization of 38.95 billion yuan [1] - 博瑞医药 is located in Suzhou Industrial Park, Jiangsu Province, and was established on October 26, 2001. The company went public on November 8, 2019, and its main business involves the research and production of high-end generic drugs and original new drugs [1] Group 2 - From the perspective of fund holdings, 长城基金 (Great Wall Fund) has one fund heavily invested in 博瑞医药. The 长城上证科创板100指数增强A (023446) fund held 28,300 shares in the second quarter, accounting for 1.85% of the fund's net value, making it the ninth largest holding. The estimated floating loss today is approximately 138,600 yuan [2] - The fund manager of 长城上证科创板100指数增强A is 雷俊 (Lei Jun), who has been in the position for 10 years and 263 days. The total asset size of the fund is 3.443 billion yuan, with the best fund return during his tenure being 153.3% and the worst being -89.53% [3]

Core Viewpoint - The biopharmaceutical sector in China is experiencing a positive trend in innovation and investment, with significant growth in the approval of innovative drugs and a recovery in market conditions [1][2] Industry Summary - As of September 8, 2025, the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) increased by 0.89%, with notable gains from companies such as United Imaging Healthcare (688271) up 11.48% and BGI Genomics (688114) up 9.35% [1] - The "National Drug Safety Publicity Week" launched on September 1 highlights the positive development of the pharmaceutical industry, with 210 innovative drugs approved in the past five years, indicating a sustained growth trend [1] - Currently, approximately 30% of the world's innovative drugs under research are from China, showcasing the country's significant role in global pharmaceutical innovation [1] Company Summary - The top ten weighted stocks in the Sci-Tech Innovation Board Biopharmaceutical Index as of August 29, 2025, include United Imaging Healthcare (688271), BeiGene (688235), and others, collectively accounting for 50.27% of the index [2] - The Sci-Tech Biopharmaceutical ETF (588250) closely tracks the performance of the Sci-Tech Innovation Board Biopharmaceutical Index, reflecting the overall performance of representative biopharmaceutical companies listed on the Sci-Tech Board [2]

Group 1 - The company will participate in a collective performance briefing for the innovative drug industry on September 16, 2025, from 15:00 to 17:00 [2][6][7] - Investors can submit questions from September 9 to September 15, 2025, through the Shanghai Stock Exchange Roadshow Center or via the company's email [2][8] - The briefing will be conducted in an interactive online format, allowing for real-time communication regarding the company's semi-annual performance and financial indicators [3][5] Group 2 - The company issued 4.65 million convertible bonds with a total value of 465 million yuan, which began trading on January 27, 2022 [11] - The initial conversion price for the bonds was set at 35.68 yuan per share, later adjusted to 35.56 yuan and subsequently to 35.05 yuan due to corporate actions [12][13] - The company has indicated that the redemption conditions for the bonds may be triggered if the stock price remains above 130% of the conversion price for a specified period [15][19]

Group 1 - The company will hold a collective performance briefing for the innovative drug industry on September 16, 2025, from 15:00 to 17:00 [1][2] - The meeting will take place at the Shanghai Stock Exchange Roadshow Center, and it will be conducted in an online text interaction format [1][2] - Investors can submit questions from September 9, 2025, to September 15, 2025, before 16:00, through the Roadshow Center website or via the company's email [2][3] Group 2 - Key participants in the meeting will include the Chairman and General Manager Yuan Jiandong, Financial Director Zou Yuanlai, Independent Director Xu Dongdong, and Board Secretary Ding Nan [2] - After the briefing, investors can view the meeting's proceedings and main content on the Shanghai Stock Exchange Roadshow Center [3]